Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Prepaid Assets of $514910.0 for Q1 2026, up 881.25% year-over-year from $52475.0 in Q1 2025, and down 48.61% quarter-over-quarter from $1.0 million in Q4 2025.
Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Prepaid Assets data on file, last reported at $514910.0 in Q1 2026.
- Prepaid Assets for Q1 2026 came in at $514910.0, up 881.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $514910.0 (up 881.25% YoY), and the FY2025 annual result was $1.0 million, up 21.24% from the prior year.
- Prepaid Assets declined to $514910.0 in Q1 2026 per IKT's latest filing, from $1.0 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $1.2 million in Q1 2022 and troughed at $52475.0 in Q1 2025.
- A 5-year average of $672245.3 and a median of $739179.0 in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2025: Prepaid Assets surged 944.5% in 2022, then sank 93.83% in 2025.
- A 5-year view of Prepaid Assets shows it stood at $1.1 million in 2022, then plunged by 33.86% to $739179.0 in 2023, then advanced by 11.81% to $826473.0 in 2024, then advanced by 21.24% to $1.0 million in 2025, then sank by 48.61% to $514910.0 in 2026.
- Business Quant data shows IKT's Prepaid Assets at $514910.0 in Q1 2026, $1.0 million in Q4 2025, and $618783.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 514,910.00 |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 618,783.00 |
| Jun 30, 2025 | 682,628.00 |
| Mar 31, 2025 | 52,475.00 |
| Dec 31, 2024 | 826,473.00 |
| Sep 30, 2024 | 112,225.00 |
| Jun 30, 2024 | 306,300.00 |
| Mar 31, 2024 | 851,057.00 |
| Dec 31, 2023 | 739,179.00 |
| Sep 30, 2023 | 347,565.00 |
| Jun 30, 2023 | 425,229.00 |
| Mar 31, 2023 | 922,764.00 |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 932,419.00 |
| Jun 30, 2022 | 811,482.00 |
| Mar 31, 2022 | 1.17 Mn |
| Dec 31, 2021 | 107,000.00 |
| Sep 30, 2021 | 264,381.00 |
| Jun 30, 2021 | 958,779.00 |